A step forward in antibiotic use and resistance monitoring: a quarterly surveillance system pilot in 11 European Union/European Economic Area countries, September 2017 to May 2020.

Peñalva, GermanCrespo-Robledo, PalomaMolvik, MariLopez-Navas, AntonioKacelnik, OliverCisneros, Jose Miguel2023-05-032023-05-032022-11-17Peñalva G, Crespo-Robledo P, Molvik M, López-Navas A, Kacelnik O, Cisneros JM, et al. A step forward in antibiotic use and resistance monitoring: a quarterly surveillance system pilot in 11 European Union/European Economic Area countries, September 2017 to May 2020. Euro Surveill. 2022 Nov;27(46):2200082.http://hdl.handle.net/10668/20506BackgroundSurveillance of antimicrobial resistance (AMR) and antimicrobial use (AMU) in Europe is currently annual.AimTo study the feasibility and scalability of a quarterly AMR/AMU surveillance system in the European Union/European Economic Area (EU/EEA).MethodsWe conducted a longitudinal study within the scope of the EU-JAMRAI project. Seventeen partners from 11 EU/EEA countries prospectively collected 41 AMU and AMR indicators quarterly from September 2017 to May 2020 for the hospital sector (HS) and primary care (PC). Descriptive statistics and coefficients of variation (CV) analysis were performed.ResultsData from 8 million hospital stays and 45 million inhabitants per quarter were collected at national (n = 4), regional (n = 6) and local (n = 7) levels. Of all partners, five were able to provide data within 3 months after each preceding quarter, and eight within 3-6 months. A high variability in AMU was found between partners. Colistin was the antibiotic that showed the highest CV in HS (1.40; p enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/EU-JAMRAIEuropeSurveillanceantibiotic useantimicrobial resistanceHumansAnti-Bacterial AgentsEuropean UnionEscherichia coliLongitudinal StudiesPilot ProjectsA step forward in antibiotic use and resistance monitoring: a quarterly surveillance system pilot in 11 European Union/European Economic Area countries, September 2017 to May 2020.research article36398580open accessEstudios longitudinalesColistinaIndicadores y reactivosTiempo de internaciónAntibacterianosVigilancia en desastresAtención primaria de salud10.2807/1560-7917.ES.2022.27.46.22000821560-7917PMC9673239https://www.eurosurveillance.org/deliver/fulltext/eurosurveillance/27/46/eurosurv-27-46-6.pdf?itemId=%2Fcontent%2F10.2807%2F1560-7917.ES.2022.27.46.2200082&mimeType=pdf&containerItemId=content/eurosurveillancehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673239/pdf